IP Library Granted Patent US 11,873,320
Granted Patent B2
US 11,873,320 · App. 17/444,594 · Granted Jan 16, 2024

2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof

Inventors: Ahmad Y. Sheikh (Deerfield, IL); Alessandra Mattei (Chicago, IL); Xiu C. Wang (Green Oaks, IL)
Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
C07J63/008A61P29/00C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,873,320
App. No.
17/444,594
Granted
Jan 16, 2024
Kind
B2
Abstract

The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.

Claims (13)

1. A method of treating a condition associated with inflammation or oxidative stress in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition comprising an active ingredient comprising a polymorphic form of a compound having the formula:

wherein the polymorphic form is crystalline, having an X-ray powder diffraction pattern (CuKα) comprising peaks at about (a) 10.601, 11.638, 12.121, 13.021, 13,435, 15.418, 15.760, 17.830, 18.753, and 19.671 °2θ, or (b) 7.552, 10.339, 11.159, 12.107, 14.729, 15.329, 15.857, 16.824, 17.994, 18.344, 19.444, 19.764, 20.801, and 22.414 °2θ; and

a pharmaceutically acceptable carrier,

wherein the condition is a skin disease or disorder selected from the group consisting of dermatitis, a chronic wound, alopecia, vitiligo, hyperkeratosis, and psoriasis.

2. The method of claim 1 , wherein the dermatitis is allergic dermatitis, atopic dermatitis, dermatitis due to chemical exposure, or radiation-induced dermatitis.

3. The method of claim 1 , wherein the chronic wound is a diabetic ulcer, a pressure sore, or a venous ulcer.

4. The method of claim 1 , wherein the alopecia is selected from baldness and drug-induced alopecia.

5. The method of claim 1 , wherein the pharmaceutical composition is administered in a single dose per day.

6. The method of claim 1 , wherein the pharmaceutical composition is administered in more than one dose per day.

7. The method of claim 1 , wherein the pharmaceutical composition is administered topically.

8. The method of claim 7 , wherein the topical administration is administered to the skin.

9. The method of claim 1 , wherein the pharmaceutical composition is formulated as a lotion, a cream, a gel, an oil, an ointment, a salve, or a suspension.

10. The method of claim 1 , wherein the amount of the active ingredient is from 0.01% to 5% by weight.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2023
From: ABBVIE INC.
To: REATA PHARMACEUTICALS HOLDINGS, LLC
Reel/Frame 065735/0609 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2022
From: ABBVIE INC.
To: REATA PHARMACEUTICALS HOLDINGS, LLC
Reel/Frame 061062/0353 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2021
From: SHEIKH, AHMAD Y.; MATTEI, ALESSANDRA; WANG, XIU C.
To: ABBVIE INC.
Reel/Frame 057102/0759 →
Continuity (5)
Continuation 16186051 · Nov 9, 2018
Continuation 15821508 · Nov 22, 2017
Continuation 14260532 · Apr 24, 2014
Provisional Application 61815502 · Apr 24, 2013
Related Publication 20220073559A1 · Mar 10, 2022
Cited By (2)
US 12,358,866 US 12,384,815